Jami Rubin - Aug 19, 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role
Chief Financial Officer
Signature
/s/ Jessica Oien, Attorney-in-Fact for Jami Rubin
Stock symbol
BOLD
Transactions as of
Aug 19, 2024
Transactions value $
$0
Form type
4
Date filed
8/20/2024, 07:03 PM
Previous filing
Jun 12, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Stock Option Disposed to Issuer -197K -100% 0 Aug 19, 2024 Common Stock 197K $4.10 Direct F1, F2
transaction BOLD Stock Option Disposed to Issuer -51.4K -100% 0 Aug 19, 2024 Common Stock 51.4K $8.19 Direct F2, F3
transaction BOLD Stock Option Disposed to Issuer -32.5K -100% 0 Aug 19, 2024 Common Stock 32.5K $16.00 Direct F2, F4
transaction BOLD Stock Option Award +197K 197K Aug 19, 2024 Common Stock 197K $3.56 Direct F1, F2, F5
transaction BOLD Stock Option Award +51.4K 51.4K Aug 19, 2024 Common Stock 51.4K $3.56 Direct F2, F3, F5
transaction BOLD Stock Option Award +32.5K 32.5K Aug 19, 2024 Common Stock 32.5K $3.56 Direct F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vested as to 25% of the underlying shares in connection with the consummation of the Issuer's initial public offering, and vests as to the remaining underlying shares in 36 substantially equal monthly installments beginning on August 31, 2024.
F2 On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 5, all other terms of the option remain unchanged.
F3 The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
F4 The stock option vests in 48 substantially equal monthly `installments beginning on April 27, 2024.
F5 The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.